An observational study in Arteriovenous Malformations, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Arteriovenous Malformations with a site in France — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Malformations · France.
Among the 15 studies in Arteriovenous Malformations with a site in France, this one is one of 2 that started in 2022, is one of 8 observational ones, and was the 13th registered.
92 studies on the registry are indexed under Arteriovenous Malformations; 29 are open to participants now.
Browse Arteriovenous Malformations studies →6 of the 15 studies in Arteriovenous Malformations with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–45 · Women only
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France, Belgium
Ages 2+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in France, United States, Brazil and 3 more countries
Ages 5+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 19 Arteriovenous Malformations studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 100 across 41 observational studies indexed under Arteriovenous Malformations.
Median enrollment 50 across the 7 interventional studies, 84 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 9 most frequent:
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
Fondation Ophtalmologique Adolphe de Rothschild has 4 studies filed under Arteriovenous Malformations — fewer than ten, so there is no comparison to draw.
4 of the studies in Arteriovenous Malformations with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05406362Vaderis Therapeutics AGAssess Safety and Efficacy of VAD044 in HHT Patients | 2027-01 |
| NCT04772963Fondation Ophtalmologique Adolphe de RothschildGenetics of Central Nervous System Arteriovenous Malformations (GENE-MAV) | 2027-02 |
| NCT04194619Hospices Civils de LyonPregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study | 2027-02 |
| NCT02042326Centre Hospitalier Universitaire, AmiensProspective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Arteriovenous Malformations with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebral and medullary arteriovenous malformations (AVMs) lead to arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. The occurrence of intracranial haemorrhage is the most important prognostic factor of AVMs because it is associated with a significant morbidity and mortality. The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known and the influence of genetic damage on the prognosis of AVMs is poorly known.
Cerebral and medullary arteriovenous malformations (AVMs) are morphologically abnormal vessels located on the surface or in the cerebral or medullary parenchyma. These vascular lesions cause the arterial and venous networks to communicate pathologically, creating an arteriovenous shunt.
The prevalence of cerebral Cerebral and medullary AVMs in general population is difficult to establish given the rarity of the condition. However, it is estimated at around 1 per 10,000 inhabitants (0.01%). About 15-20% of the cerebral vascular accidents are asymptomatic at the time of diagnosis. The occurrence of intracranial haemorrhage is the most important prognostic factor because it is associated with a significant morbidity and mortality. The management of an AVM is usually carried out in a multidisciplinary way, combining interventional neuroradiology, neurosurgery and vascular neurology.
The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known. Several recent research works highlight mutations in the RAS-MAPK or MAPK-ERK signalling pathway in AVMs. In cases of cerebral AVMs considered to be sporadic, a somatic KRAS/BRAF mutation has recently been demonstrated in tissue samples of operated AVMs.
Except in the case of Hereditary Haemorrhagic Telangiectasia (HHT or Rendu-Osler-Weber syndrome), the influence of genetic damage on the prognosis of AVM is poorly known. It is also interesting to note that genetic screening is not routinely performed in patients with cerebro-medullary AVMs and that therefore the prevalence of these clinical entities in patients with AVMs is not known.
The recruited population will be index cases with cerebrovascular cerebral vascular malformations treated in the participating centres
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
During the arteriography a peripheral venous sampling
Genetic mutation
Presence of a pathogenic mutation in one of the genes tested in the panel or identification of a pathogenic mutation following sequencing of the exome and/or transcriptome of the patient and/or his/her parents.
Time frame: limit of 12 month
Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Feb 2027, on Nov 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Ophtalmologique Adolphe de Rothschild →